SETH LERNER to Urologic Neoplasms
This is a "connection" page, showing publications SETH LERNER has written about Urologic Neoplasms.
Connection Strength
2.175
-
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2021 06; 87(6):799-805.
Score: 0.728
-
Highlights of the 2010 SUO Annual Meeting. Urol Oncol. 2011 Nov-Dec; 29(6):825.
Score: 0.381
-
Overview of SUO Winter 2008 proceedings. Urol Oncol. 2010 Jan-Feb; 28(1):67-8.
Score: 0.335
-
Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
Score: 0.210
-
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol. 2017 02; 71(2):237-246.
Score: 0.133
-
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs. 2014 Sep; 25(8):878-86.
Score: 0.116
-
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3377-82.
Score: 0.115
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.086
-
Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
Score: 0.072